Ring Nitrogen Is Shared By Two Of The Cyclos (e.g., Ergot, Alkaloids, Etc.) Patents (Class 544/346)
-
Publication number: 20140179706Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20140179704Abstract: 8?-Hydroxy-Dihydroergotamine (8?-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of migraine disorders using the compounds, compositions, dosage forms and administration techniques disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: Donald J. Kellerman, Thomas Armer, Jian Zhang
-
Publication number: 20140179705Abstract: 8?-Hydroxy-Dihydroergotamine (8?-OH DHE) medicinal compounds, compositions, and dosage forms containing such compositions are provided. Also provided herein are methods of treatment, prevention, or amelioration of diseases, conditions or disorders selected from amyotrophic lateral sclerosis (ALS), Parkinson's disease, stress/anxiety, nausea, emesis, aggression, pain, neuropathic pain, sleeplessness, insomnia, restless leg syndrome and depression using the compounds, compositions, dosage forms and administration techniques disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20140179707Abstract: Provided herein are 8?-Hydroxy-2-CF3-dihydroergotamine (8?OH-2-CF3-DHE) compounds, compositions, and dosage forms containing such compositions. Also provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: December 19, 2013Publication date: June 26, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Thomas Armer, Shashidhar Kori, Libo Wu
-
Publication number: 20140147386Abstract: The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE 10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET).Type: ApplicationFiled: June 26, 2012Publication date: May 29, 2014Applicant: Janssen Pharmaceutica NVInventors: José Ignacio Andrés-Gil, Peter Jacobus Johannes Antonius Buijnsters, Andrés Avelino Trabanco-Suárez, Meri De Angelis, Greta Constantia Peter Vanhoof, Jérôme Emile Georges Guillemont, Frederik Jan Rita Rombouts, Maarten Vliegen, Guy Maurits R. Bormans, SofleJeanne Leopoldine Celens
-
Patent number: 8729082Abstract: The present invention relates to substituted imidazoquinoxaline compounds of general formula (I) as inhibitors of Mps-1 Kinase or TTK, and being active against inflammation and cancer.Type: GrantFiled: April 24, 2010Date of Patent: May 20, 2014Assignee: Bayer Intellectual Property GmbHInventors: Marcus Koppitz, Benjamin Bader, Ulf Bömer, Bertolt Kreft, Philip Lienau, Tobias Marquardt, Stefan Prechtl, Gerhard Siemeister, Christof Wegscheid-Gerlach
-
Publication number: 20140121198Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.Type: ApplicationFiled: October 31, 2013Publication date: May 1, 2014Applicant: Incyte CorporationInventors: Yun-Long Li, Wenyu Zhu, Song Mei, Joseph Glenn
-
Publication number: 20140107126Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof.Type: ApplicationFiled: September 17, 2013Publication date: April 17, 2014Inventors: Hervé GENESTE, Michael OCHSE, Karla DRESCHER, Clarissa JAKOB, Maricel TORRENT
-
Patent number: 8674096Abstract: Substituted imidazo[1,5-a]quinoxalin-4-ones are useful as phosphodiesterase 9 inhibitors.Type: GrantFiled: November 27, 2012Date of Patent: March 18, 2014Assignee: Astellas Pharma Inc.Inventors: Hiroyuki Kaizawa, Mari Sugita, Hidenori Azami, Ryushi Seo, Takaho Nomura, Satoshi Yamamoto, Hirofumi Yamamoto, Kazuyuki Tsuchiya, Hideki Kubota, Kazunori Kamijo
-
Publication number: 20140073790Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 7, 2013Publication date: March 13, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 8669362Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.Type: GrantFiled: September 5, 2013Date of Patent: March 11, 2014Assignees: Shiongi & Co., Ltd., VIIV Healthcare CompanyInventors: Brian Johns, Maosheng Duan, Toshikazu Hakogi
-
Publication number: 20140051697Abstract: The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.Type: ApplicationFiled: October 23, 2013Publication date: February 20, 2014Applicant: Biota Scientific Management Pty Ltd.Inventors: Jeffrey Peter Mitchell, Gary Pitt, Alistair George Draffan, Penelope Anne Mayes, Laura Andrau, Kelly Helen Anderson
-
Publication number: 20140051689Abstract: Compounds of formula (I), and their use as in the treatment of infections involving viruses of the Pneumovirinae sub-family (RSV) are disclosed. In the formula ring (A) may be phenyl, pyridyl etc., (B-C) may be CH2—CH2 etc., (R1) may be phenyl and substituted forms thereof, (R2) may be assorted substituents.Type: ApplicationFiled: October 24, 2013Publication date: February 20, 2014Applicant: Biota Scientific Management Pty Ltd.Inventors: Silas Bond, Vanessa Anne Sanford, John Nicholas Lambert, Chin Yu Lim, Alistair George Draffan, Roland Henry Nearn, Jeffrey Peter Mitchell
-
Publication number: 20140045857Abstract: The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.Type: ApplicationFiled: July 26, 2013Publication date: February 13, 2014Applicant: Boehringer Ingelheim International GmbHInventors: Riccardo GIOVANNINI, Barbara BERTANI, Sara FRATTINI, Giustino DI ANTONIO
-
Publication number: 20140045856Abstract: The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.Type: ApplicationFiled: July 18, 2013Publication date: February 13, 2014Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Riccardo GIOVANNINI, Barbara BERTANI, Sara FRATTINI, Giustino DI ANTONIO
-
Publication number: 20140038976Abstract: The invention relates to novel piperazine compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Cav2.2 calcium channels is beneficial, i.e. in particular to treat pain.Type: ApplicationFiled: January 19, 2012Publication date: February 6, 2014Inventors: David Norton, Daniele Andreotti, Simon E. Ward, Roberto Profeta, Simone Spada, Helen Susanne Price
-
Publication number: 20140039188Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: MAP PHARMACEUTICALS, INC.Inventors: Jian Zhang, Robert O. Cook
-
Publication number: 20140011995Abstract: A process for preparing a compound represented by formula (Y1) or (Y2) [wherein Rx is an optionally substituted carbocyclyl lower alkyl, or the like] or a salt thereof, using a novel process for preparing a pyridone derivative represented by formula (X4) [wherein R1d is hydrogen, halogen, or the like; R2d is hydrogen, a lower alkyl optionally substituted with substituent E, or the like; R4d is a lower alkyl optionally substituted with substituent E, or the like; and R6d is a lower alkyl group optionally substituted with substituent group E, or the like].Type: ApplicationFiled: August 4, 2011Publication date: January 9, 2014Inventors: Yukihito Sumino, Moriyasu Masui, Diasuke Yamada, Fumiya Ikarashi, Kazuya Okamoto
-
Patent number: 8604034Abstract: The present invention relates to compounds of formula (I) its salts, isomers or prodrugs thereof useful in the treatment of viral infections, in particular respiratory syncytial virus (RSV) infections. The present invention also relates to processes for preparing the compounds and intermediates used in their preparation.Type: GrantFiled: February 8, 2011Date of Patent: December 10, 2013Assignee: Biota Scientific Management Pty Ltd.Inventors: Jeffrey Peter Mitchell, Gary Pitt, Alistair George Draffan, Penelope Anne Mayes, Laura Andrau, Kelly Anderson
-
Patent number: 8604035Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: GrantFiled: June 22, 2012Date of Patent: December 10, 2013Assignee: Map Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Patent number: 8592445Abstract: Provided herein are novel iso-ergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1Breceptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2Breceptors using the compounds and compositions disclosed herein.Type: GrantFiled: June 22, 2012Date of Patent: November 26, 2013Assignee: MAP Pharmaceuticals, Inc.Inventors: Jian Zhang, Robert O. Cook
-
Patent number: 8592424Abstract: A method of treating a disease state or condition in humans via topical brainstem afferent stimulation therapy via the administration of a drug to the back of the neck of a human patient at the hairline in close proximity to and under or on the area of skin above the brain stem to provide regional neuro-affective therapy is disclosed.Type: GrantFiled: June 29, 2009Date of Patent: November 26, 2013Assignee: Afgin Pharma LLCInventor: Ronald Aung-Din
-
Publication number: 20130296329Abstract: The present inventors have investigated a compound which has a PDE9-inhibitory action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibitory action, thereby completing the present invention.Type: ApplicationFiled: March 7, 2013Publication date: November 7, 2013Inventors: Hiroyuki KAIZAWA, Mari SUGITA, Hirofumi YAMAMOTO, Kazunori KAMIJO, Kazuyuki TSUCHIYA, Ryushi SEO, Satoshi YAMAMOTO
-
Patent number: 8563565Abstract: A compound and/or pharmacologically acceptable salt thereof represented by the formula (I) has PDE9 inhibitory action, so that the intracerebral cGMP concentration is anticipated to be elevated. The PDE9 inhibitory action and the increase in cGMP lead to the improvement of learning and memory behaviors, and the compound (I) has a potential use of a therapeutic agent for cognitive dysfunctions in Alzheimer's disease. wherein R1 is a hydrogen atom; R2 is an aromatic ring group, etc.; R3 is a hydrogen atom, etc; R4 is a hydrogen atom; R5 is an oxepanyl group, etc.; R6 is a hydrogen atom.Type: GrantFiled: October 4, 2012Date of Patent: October 22, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Yoshihiko Norimine, Kunitoshi Takeda, Koji Hagiwara, Yuichi Suzuki, Yuki Ishihara, Nobuaki Sato
-
Publication number: 20130274239Abstract: Disclosed are compounds of the following formula: in which R1, R2, R3, R4, R5, R6, R7, X, and t are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.Type: ApplicationFiled: May 8, 2013Publication date: October 17, 2013Inventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. A. Kiryanov
-
Patent number: 8552187Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.Type: GrantFiled: December 9, 2009Date of Patent: October 8, 2013Assignees: Shionogi & Co., Ltd., VIIV Healthcare CompanyInventors: Brian Alvin Johns, Maosheng Duan, Toshikazu Hakogi
-
Patent number: 8524902Abstract: The present invention relates to compounds useful as inhibitors of protein kinase, represented by Structural Formula (I): wherein the variables in Structural Formula (I) are as described herein. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.Type: GrantFiled: October 5, 2011Date of Patent: September 3, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Jean-Damien Charrier, David Kay, Ronald Knegtel
-
Publication number: 20130225572Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: ApplicationFiled: September 14, 2012Publication date: August 29, 2013Inventors: Makoto OKADA, Shuichiro SATO, Kenji KAWADE, Kotaro GOTANDA, Atsushi SHINBO, Youichi NAKANO, Hideo KOBAYASHI
-
Publication number: 20130216497Abstract: The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: February 7, 2013Publication date: August 22, 2013Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
-
Patent number: 8513250Abstract: The invention relates to Imidazolo-heteroaryl derivatives of formula (I). The compounds inhibit the activity of the Dlta enzyme of Gram-positive bacteria and are useful to treat Gram-positive bacterial infections. Furthermore the application discloses method for assessing the Dlta inhibitory activity of tested molecules and a method for measuring the efficacy of molecules in inhibiting bacteria proliferation in vitro.Type: GrantFiled: March 21, 2008Date of Patent: August 20, 2013Assignee: Laboratoire BiodimInventors: Sonia Escaich, Alexis Denis, Vincent Gerusz, François Moreau, Mayalen Oxoby, Yannick Bonvin
-
Publication number: 20130203762Abstract: This present invention relates to an antiprolactinic veterinary composition to be administered to ruminants. Said composition comprises at least one antiprolactinic compound which is an agonist of dopamine receptors, and is particularly useful for reducing udder engorgement and/or the reduction of pain after drying off and/or of increasing welfare, and/or of reducing milk leakage in ruminants as well as for preventing new mammary microbial infections, secondary infection, or co-infections in ruminants and mastitis.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: CEVA SANTE ANIMALEInventor: CEVA SANTE ANIMALE
-
Publication number: 20130190307Abstract: Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.Type: ApplicationFiled: September 15, 2011Publication date: July 25, 2013Inventors: Weiguo Su, Weihan Zhang, Haibin Yang
-
Publication number: 20130178468Abstract: Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.Type: ApplicationFiled: September 7, 2012Publication date: July 11, 2013Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C. A. Isaccs, Wei Han, Melissa Egbertson, Richard Pracitto
-
Publication number: 20130172551Abstract: The present invention relates to the preparation of carbamoylpyridone derivatives and intermediates.Type: ApplicationFiled: March 22, 2011Publication date: July 4, 2013Inventors: Steven N. Goodman, Huan Wang, Douglas Matthew Mans
-
Publication number: 20130137680Abstract: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5 and n are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.Type: ApplicationFiled: December 1, 2010Publication date: May 30, 2013Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Stephen James Boyer, Jennifer Burke, Xin Guo, Thomas Martin Kirrane, JR., Roger John Snow, Yunlong Zhang
-
Patent number: 8450323Abstract: Disclosed are compounds of the following formula: in which R1, R2, R6, R7, R12, X, and q are defined in the specification. Also disclosed are pharmaceutical compositions, kits, and articles of manufacture, which contain the compounds, methods and intermediates useful for making the compounds, and methods of using the compounds to treat diseases, disorders, and conditions related to PARP activity.Type: GrantFiled: January 18, 2012Date of Patent: May 28, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Anthony R. Gangloff, Andrew John Jennings, Benjamin Jones, Andre A. Kiryanov
-
Patent number: 8435994Abstract: The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “Fused Tricyclic Compounds”), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.Type: GrantFiled: November 12, 2010Date of Patent: May 7, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Joel M. Harris, Bernard R. Neustadt, Andrew W. Stamford
-
Publication number: 20130101622Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).Type: ApplicationFiled: May 7, 2012Publication date: April 25, 2013Applicant: Novartis AGInventors: James SUTTON, Feng Xu, Nicholas Valiante, Jiong Lan
-
Patent number: 8410103Abstract: The present invention is directed to a substituted 2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2 -a]pyrido[1,2-d]pyrazine-5,7-dione useful as an anti-HIV agent, which has the formula: as well as pharmaceutically acceptable salts thereof, compostions thereof, and methods of use thereof.Type: GrantFiled: January 18, 2012Date of Patent: April 2, 2013Assignees: Shionogi & Co., Ltd., VIIV Healthcare CompanyInventors: Brian Alvin Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
-
Publication number: 20130072470Abstract: The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.Type: ApplicationFiled: September 20, 2012Publication date: March 21, 2013Applicant: ABBVIE INC.Inventors: Neil Wishart, Dominique F. Bonafoux, Kristine E. Frank, Adrian D. Hobson, Donald B. Konopacki, Gloria Y. Martinez, Lu Wang
-
Patent number: 8389524Abstract: Tricyclic nitrogen containing compounds and their use as antibacterials. Z1 and Z2 are independently selected from CH and N.Type: GrantFiled: April 16, 2008Date of Patent: March 5, 2013Assignee: Glaxo Group LimitedInventors: David Evan Davies, David Thomas Davies, Ilaria Giordano, Alan Joseph Hennessy, Neil David Pearson
-
Patent number: 8383825Abstract: The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.Type: GrantFiled: July 7, 2011Date of Patent: February 26, 2013Assignee: Allergan, Inc.Inventors: Lon T. Spada, Jane Guo Shiah, Patrick Hughes, Thomas C. Malone, Gerald W. Devries, Jeffrey L. Edelman, Julie A. Wurster
-
Patent number: 8378098Abstract: Imidazo[1,2-a]quinoxaline compounds for the treatment of cancers as well as pharmaceutical compositions that include these compounds and their uses in therapy.Type: GrantFiled: October 3, 2008Date of Patent: February 19, 2013Assignees: Universite de Montpellier I, American University of Beirut, Centre Regional de Lutte Contre le Cancer de MontpellierInventors: Carine Deleuze-Masquefa, Georges Moarbess, Pierre-Antoine Bonnet, Frédéric Pinguet, Ali Bazarbachi, Françoise Bressolle
-
Publication number: 20130040943Abstract: This disclosure relates to compounds of formula I: wherein R1, R2, R3, R4, X and Y have the meanings denoted in the disclosure. The compounds of formula I have antithrombotic activity and in particular inhibit the protease-activated receptor 1 (PAR1). The disclosure further relates to a method for producing the compound of formula I and to the use thereof as a pharmaceutical product.Type: ApplicationFiled: October 16, 2012Publication date: February 14, 2013Applicant: SANOFIInventor: SANOFI
-
Patent number: 8361962Abstract: The present invention relates to the use of novel compounds of Formulae I-II, wherein the variables R, X1, X2, X3, Y1, Y2, Y3, Z1, and Z2 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.Type: GrantFiled: June 29, 2010Date of Patent: January 29, 2013Assignee: Roche Palo Alto LLCInventor: Roland Joseph Billedeau
-
Publication number: 20130023524Abstract: Tricyclic indazole compound and its pharmaceutically acceptable salts of acid addition, use thereof, method and intermediates for preparing them, and a pharmaceutical composition containing them. The tricyclic indazole compound has the following general Formula (I): in which R1, R2, L1, L2, X1, X2, X3, X4, X5, Y, W, m, and n have the meanings stated in the description.Type: ApplicationFiled: March 4, 2011Publication date: January 24, 2013Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.Inventors: Maria Alessandra Alisi, Nicola Cazzolla, Guido Furlotti, Beatrice Garrone, Gabriele Magaro', Giorgina Mangano
-
Patent number: 8357688Abstract: Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones are useful as PDE9 inhibitors.Type: GrantFiled: March 4, 2010Date of Patent: January 22, 2013Assignee: Astellas Pharma Inc.Inventors: Hiroyuki Kaizawa, Mari Sugita, Hidenori Azami, Ryushi Seo, Takaho Nomura, Satoshi Yamamoto, Hirofumi Yamamoto, Kazuyuki Tsuchiya, Hideki Kubota, Kazunori Kamijo
-
Publication number: 20120329806Abstract: Provided herein are novel fluoroergoline derivatives and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, migraine using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of agonizing receptors such as, for example, the 5-HT1D and/or the 5-HT1B receptor, without agonizing the 5-HT2B receptor using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing or inhibiting activity at receptors such as, for example, the adrenergic alpha2A and/or the alpha2B receptors using the compounds and compositions disclosed herein.Type: ApplicationFiled: June 22, 2012Publication date: December 27, 2012Applicant: MAP Pharmaceuticals, Inc.Inventors: Robert O. Cook, Jian Zhang, Thomas A. Armer
-
Publication number: 20120302564Abstract: The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.Type: ApplicationFiled: January 30, 2012Publication date: November 29, 2012Inventors: Hans-Joachim Lankau, Barbara Langen, Christian Grunwald, Norbert Hoefgen, Hans Stange, Rita Dost, Ure Egerland
-
Patent number: 8299080Abstract: The invention discloses quinoxaline derivatives or salts thereof having PDE9-inhibiting activity and being useful as treating agent of dysuria and the like, which are represented by the formula (I) in the formula, R1 and R2 each independently stands for hydrogen, halogen, alkyl, alkoxy, acyl, amino and the like, R3 stands for alkyl, aryl, saturated carbocyclic group, saturated heterocyclic group, acyl and the like, R4 stands for hydrogen, hydroxy, alkyl or amino, R5 and R8 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkoxy, cyano or nitro, R6 and R7 each independently stands for hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxy, cyano, amino, carbocyclic group, heterocyclic group, COR9 or SO2R9, R9 stands for hydrogen, hydroxy, alkyl, amino, pyrrolidin-1-yl, piperidin-1-yl, pyperazin-1-yl or the like, X stands for S or O, and A1, A2 and A3 each independently stands for N or C.Type: GrantFiled: December 12, 2007Date of Patent: October 30, 2012Assignee: Aska Pharmaceutical Co., Ltd.Inventors: Makoto Okada, Shuichiro Sato, Kenji Kawade, Kotaro Gotanda, Atsushi Shinbo, Youichi Nakano, Hideo Kobayashi